Atreya, Raja

P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241

10.1136/gutjnl-2026-bsg.373